{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0006954",
      "entity_text" : "inflammation",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P37231",
      "entity_text" : "PPARgamma",
      "entity_type" : "protein"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "We hypothesized that the specific delivery of a PPARgamma agonist to inflamed plaques could reduce plaque burden and inflammation without systemic adverse effects.",
  "reading_complete" : "2020-08-03T10:35:45Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T10:34:15Z",
  "trigger" : "reduce",
  "evidence" : [ "PPARgamma agonist to inflamed plaques could reduce plaque burden and inflammation" ],
  "pmc_id" : "5743459",
  "score" : 0
}